Alphavirus replicons encoding IFNγ enhance cancer virotherapy by overcoming macrophage-mediated suppression

Interference by tumor-associated macrophages may significantly reduce the efficacy of therapeutic viruses designed to infect cancer cells and activate antitumor T-cells. Using a computational model, we hypothesized that viruses encoding a T cell-stimulating signal, like IFN-{gamma}, could overcome this barrier. We engineered an alphavirus-based replicon expressing IFN-{gamma} and evaluated its effect in various human-derived tumor-immune coculture systems and an in vivo murine model. While alphavirus replicons do not replicate in macrophages, macrophages acted as a barrier, limiting tumor infection in a frequency-dependent but phenotype-independent manner. Nonetheless, T-cell activation occurred even when only a fraction of infected tumor cells expressed IFN-{gamma}, regardless of macrophage presence, frequency, or phenotype. Additionally, viral stimulation drove macrophage-repolarization towards a pro-inflammatory phenotype favoring T-cell activation. These findings highlight a strategy for optimizing virotherapy in macrophage-rich tumors by designing viruses that stimulate T-cell activation, ensuring therapeutic efficacy.